Krystal Biotech, Inc. research snapshot
KRYS AI stock analysis currently reads Krystal Biotech, Inc. as a commercial-stage genetic medicine company whose economics are led by VYJUVEK for dystrophic epidermolysis bullosa, with high gross margins, rising profitability, a cash-rich balance sheet, and a still-concentrated product base. At the July 12, 2026 data cutoff, KRYS traded near $365.81 with a verified market capitalization of about $10.78 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$365.81
Market cap
$10.78 billion
AI score
68 / 100
Rating
Commercial gene-therapy leader with high margins, VYJUVEK concentration, and premium valuation
Trend status
Strong multi-timeframe uptrend near the 52-week high, setup quality still extended
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Krystal sells redosable HSV-1 gene therapy, led by VYJUVEK for DEB, converting molecular correction of COL7A1-related disease into recurring product revenue with roughly 94% to 95% gross margins. | High |
| Moat | The moat rests on first-in-class commercial proof in DEB, redosable topical gene-therapy know-how, patents and exclusivity, specialist relationships, manufacturing control, and growing real-world use. It is product-led rather than broad network-effect based. | Medium-high |
| Management | Founders Krish Krishnan (Chairman and CEO) and Suma Krishnan (President, R&D) have taken VYJUVEK from concept to multi-region commercial product and funded a broader pipeline without heavy debt, but the equity story remains closely tied to founder execution. | Medium-high |
| Financial trend | FY2025 product revenue rose to $389.1 million, FY2025 net income reached about $204.8 million, and Q1 2026 VYJUVEK revenue of $116.4 million rose 32% year over year with 95% gross margin. | High |
| Valuation | At $365.81, KRYS traded near 51.7x FY2025 EPS of $7.08, about 49.6x TTM EPS of $7.38, roughly 8.5x book value, and about 26x trailing sales, a premium for a concentrated rare-disease franchise. | Medium-high |
| Technical trend | ChartMill rated technicals 10/10 with both short- and long-term trends up, price above the 50-day and 200-day averages, support near $366 and $331, and resistance near $372 to $378. | Medium |
| Risk level | Main risks are VYJUVEK concentration, DEB market-size and adherence limits, reimbursement and pricing pressure, pipeline trial setbacks, founder key-person risk, and valuation compression after a large multi-year run. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks reprice around trial, payer, competitive, and regulatory news. | High data confidence |
| Investment certainty | Medium certainty. Cash generation and margins support the business, but the stock needs sustained VYJUVEK growth and pipeline progress to justify the premium multiple. | Medium |
KRYS AI stock forecast
The KRYS AI stock forecast uses scenario math around the $365.81 quote and FY2025 EPS of $7.08. The audited three-year framework produced a bullish area near $817, a base area near $431, and a bearish area near $177 before any future dilution, acquisitions, or major clinical events.
$780 to $850
More likely if VYJUVEK keeps growing through U.S. depth and Europe and Japan expansion, 2026 KB803 and KB801 registrational data de-risk the platform, cash generation funds the pipeline without dilution, and investors keep paying a high-growth biotech multiple.
$410 to $450
More likely if VYJUVEK revenue compounds at a solid mid-teens pace, margins stay high, pipeline news is mixed rather than transformative, and valuation settles closer to a mature profitable rare-disease multiple.
$160 to $190
More likely if VYJUVEK growth stalls, international reimbursement disappoints, clinical readouts fail, competitive gene therapies or wound-care options cut share, or the multiple compresses toward a lower earnings multiple after the 2025-2026 rerating.
KRYS AI technical analysis
KRYS AI technical analysis is constructive but extended as of the July 12, 2026 cutoff. ChartMill listed a $365.81 close, a 10/10 technical rating, a weaker 4/10 setup score, support near $365.80 and $330.81, resistance from $372.44 to $378.16, and price above rising 50-day and 200-day simple moving averages.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $365.81 | ChartMill close used for the July 12, 2026 research snapshot and market-cap math with 29.48 million shares. |
| Near support | $365 to $366 | ChartMill listed a support zone at $365.80 formed by multiple trend lines, close to the latest trade area. |
| Secondary support | $331 | ChartMill listed daily trend-line support near $330.81, an important pullback reference if the near-term zone fails. |
| Deeper support | $288 to $294 | ChartMill listed further support near $293.90 weekly and $287.39 daily if a deeper mean reversion develops. |
| Moving averages | Bullish stack | SMA(20) $354.65, SMA(50) $320.96, and SMA(200) $259.19 were all below price, with both short- and long-term ChartMill trends up. |
| Resistance | $372 to $378 | ChartMill listed the first major resistance zone from $372.44 to $378.16 near recent highs. |
| Higher resistance | $382.54 | The 52-week high near $382.54 is the next ceiling after the $372 to $378 band. |
| Momentum | Strong but not clean for entry | Daily RSI was 62.62 and weekly RSI was overbought near 74.11. ChartMill flagged a bull-flag pattern but only a 4/10 setup score because price was volatile and extended. |
| Volume | Event-sensitive biotech volume | Average volume was about 332K shares. Volume should be checked against earnings, VYJUVEK demand updates, KB803 and KB801 data, and FDA designation news. |
| Volatility | Medium-high for a profitable biotech | ChartMill ATR was about 3.8% of price. Expect larger moves around product metrics, clinical readouts, and rare-disease policy or pricing headlines. |
| Invalidation | Close below $331, then $288 | A decisive break below $331 would weaken the short-term swing setup. A break below the $288 to $294 band would force a deeper thesis and multiple review. |
KRYS AI trading strategy
The KRYS AI trading strategy is a rules-based framework for a profitable rare-disease biotech with product concentration, pipeline optionality, and event risk. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical or regulatory event checks.
Watch for KRYS to hold above the $365 to $366 and $331 supports, stay above the rising 50-day average near $321, and retest the $372 to $378 resistance band with confirming volume and no negative product or trial news.
A close below $331 should invalidate the short-term swing setup. A close below $288 to $294 should force a full review of VYJUVEK growth, pipeline news, and valuation assumptions.
If KRYS pulls back toward $331 or the $288 to $294 zone without a new clinical, payer, or competitive problem, compare the price move with Q1 product growth, cash generation, and upcoming KB803 or KB801 catalysts.
Do not treat every pullback as mean reversion. Biotech support levels can fail fast when trial readouts, reimbursement, or product-concentration risks change.
Track VYJUVEK net product revenue and gross margin, U.S. versus ex-U.S. uptake, cash and investments, debt, share dilution, KB803, KB801, KB407, KB111, KB707 milestones, and any pricing or access headlines.
Reduce confidence if valuation depends mainly on a premium multiple rather than durable VYJUVEK cash flow and de-risked pipeline data.
Investment research summary
Customers and payers pay Krystal when VYJUVEK and future genetic medicines deliver usable, redosable molecular correction for rare diseases with high unmet need. The core business is converting HSV-1 gene-delivery science into commercial therapy revenue.
The moat is strongest where first commercial proof in DEB, intellectual property, manufacturing know-how, specialist trust, and real-world durability reinforce each other. It narrows if rivals match convenience, outcomes, access, or price, or if the addressable DEB pool proves smaller than expected.
The thesis fails if VYJUVEK growth slows faster than expected, international launches underdeliver, clinical programs disappoint, pricing pressure cuts net revenue, key founders or R&D leadership change, or valuation multiples compress before pipeline value is proven.
Krish and Suma Krishnan have executed from platform company to profitable commercial biotech with low leverage and more than $1 billion in cash and investments at Q1 2026. The next test is capital allocation across pipeline breadth without diluting the VYJUVEK franchise story.
Genetic medicines sit inside a long-term shift toward molecularly precise therapies. Redosable topical or local gene delivery can be durable if safety, manufacturing cost, reimbursement, and real-world adherence hold, but the category remains high-event and regulation-sensitive.
KRYS is priced for continued VYJUVEK growth and meaningful pipeline success. Margin of safety is limited at roughly 50x earnings and mid-20s sales, and improves only if product cash flow compounds while clinical data expand the multi-product platform case.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KRYS price | $365.81 | ChartMill technical analysis close | July 12, 2026 |
| Market capitalization | $10.78 billion, verified as $365.81 x 29.48 million shares | financial_rigor.py market cap verification, Morningstar, and MarketBeat | July 12, 2026 |
| Shares outstanding | 29.48 million | Morningstar and Google Finance cross-check | July 12, 2026 |
| FY2025 product revenue | $389.1 million, up from $290.5 million in 2024 | Krystal Biotech FY2025 earnings release and Macrotrends | July 12, 2026 |
| FY2025 net income and EPS | About $204.8 million net income and $7.08 EPS | Simply Wall St full-year 2025 summary cross-checked with TTM math | July 12, 2026 |
| Q1 2026 VYJUVEK product revenue | $116.4 million, up 32% year over year, 95% gross margin | Krystal Biotech Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 net income and diluted EPS | $55.9 million net income and $1.83 diluted EPS | Krystal Biotech Q1 2026 earnings release | July 12, 2026 |
| Cash and investments | About $1.02 billion total cash, short-term, and long-term investments at March 31, 2026; cash and short-term investments about $823.4 million | Krystal Biotech Q1 2026 balance sheet and Yahoo Finance cash cross-check | July 12, 2026 |
| TTM valuation snapshot | TTM EPS about $7.38, PE about 49.6x, PB about 8.5x, levered FCF TTM about $137.5 million | Yahoo Finance key statistics and financial_rigor.py valuation check | July 12, 2026 |
| Technical support and resistance | Support $365.80 then $330.81; resistance $372.44 to $378.16; SMA50 $320.96; SMA200 $259.19 | ChartMill technical analysis | July 12, 2026 |
This KRYS AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
